Latest News and Press Releases

This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and procurement of Ebanga™, with a maximum value of $704 millionProgram progress and performance...

GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the...

Emergent BioSolutions today announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax®

GAITHERSBURG, Md., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the...

PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and Prevention GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:...

Third Quarter 2024 Total Revenues of $293.8 million, increase of 9% versus prior yearThird Quarter 2024 Net Income of $114.8 million, increase of 144% versus prior yearThird Quarter 2024 Adjusted...

Executive Management Team appointments contribute to Emergent’s transformation and beyond, including promotion of Jessica Perl to General Counsel and Corporate Secretary GAITHERSBURG, Md., Nov. 04,...

GAITHERSBURG, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2024, at 5:00 pm eastern time to discuss the...

Ongoing support of the ‘White House Challenge to Save Lives from Overdose’ through workplace and public safety measuresOne-year mark of Ready to Rescue public awareness campaign to expand awareness,...

GAITHERSBURG, Md., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it entered into a new credit agreement on September 30, 2024 providing for an...